What the approved medicine is for
Tesamorelin is a lab-made version of growth hormone-releasing hormone. It prompts the pituitary gland in the brain to release growth hormone, which raises IGF-1, a growth factor. That puts it near CJC-1295 in the conversation, but gives neither compound the other’s results.
Tesamorelin (Egrifta) is FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy—a change in how body fat is distributed. Its prescribing information says it isn’t for weight-loss management. That limit is part of the finding.
Who was studied belongs in the sentence about what worked.
Some doctors and pharmacies also prescribe compounded tesamorelin. Compounded medicines aren’t FDA-approved. I keep that route distinct from Egrifta, so that an approved product’s evidence doesn’t quietly become an approval claim for every preparation carrying the same ingredient name.
The scan and the scale told different stories
Visceral fat is the deeper fat around internal organs. In a major tesamorelin trial, that fat fell in adults with HIV and excess abdominal fat. Body weight barely changed. A scan could show a change without the scale showing much movement.
Less deep fat didn’t mean much less weight.
That’s why I’m careful with the phrase “fat loss” here. It names a specific result in a specific group, rather than a general slimming effect. It also doesn’t establish what CJC-1295 with ipamorelin would do.
The change didn’t reliably stay after treatment stopped. In follow-up research, people switched to placebo—a dummy treatment—regained visceral fat. That matters if you’re trying to understand whether the result was a lasting change after a course ended.
A real benefit still comes with cautions
The label warns about fluid retention, raised blood sugar and high IGF-1. It says the effects of prolonged IGF-1 elevation are unknown. It also rules out use in pregnancy, active cancer and certain disorders affecting the pituitary hormone system.
Those warnings aren’t proof that tesamorelin causes cancer. They do help explain why a treatment decision needs more than an appealing scan result. The label calls for blood-sugar checks and IGF-1 monitoring, and leaves long-term heart and blood vessel safety unresolved.
A useful result leaves other questions to answer.
I find the comparison page useful at this point. It separates a hormone result, a meal after surgery and this visceral-fat finding. Each tells us something worth knowing, without turning the three into interchangeable options for the same person.